2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧46 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·23 t sittenPerhaps it's been said, but Onco is being heavily shorted because the expectation is that the price will go down in connection with the issue. This means that a number of millions of shares will be bought back from the short sellers and the price should then make an upward rebound next week.
·18 t sittenDidn't go down last time, probably won't go down now... so that will be great!!- ·1 päivä sittenOn its way up again!? The 40% drop came immediately after the emission announcement (dilution 33%), which means that most of the negative etc. is already priced in! The emission of approx. 200 Mkr secures financing for the Pepaxti launch in Europe and according to RedEye financing until 2027 with a base target price of 2.8. Pepaxti sales have shown strong growth historically. The gross margin is very high around 98%, which means that profitability can come quickly with volume scaling. Biotech often bottoms out around financing concerns, and once capital is secured, the focus usually shifts back to sales and pipeline.
·1 päivä sittenI largely agree with you. There are two simple details here and that is the operating revenues that have increased significantly. If one gets revenues to increase, it often means market shares which in turn means acceptance in the market for the products. Then it's just the rest to sort out..... 😉 - ·1 päivä sittenRegardless of what one believes & hopes for the future, today is the last day to buy shares for those who want to participate in the new share issue at 1,55kr. As RedEye wrote, current cash + contribution from FE is expected to last until 2027... with a base price of 2,8 as a guideline until more positive news comes, and there's a lot brewing, so who knows when it will take off. 1,55 feels regardless like a really good buy in my opinion.
·1 päivä sittenHippo: I believe in a bright future regarding ONCO. I also intend to participate in the new share issue. BUT how big is the chance that one actually gets to participate even if one owns shares today? It's already 90% subscribed by the major shareholders? Then there are certainly those who have submitted by mail to the company that they want allocation and are first in line. I think the chance is small. Or are you of a different opinion?·1 päivä sittenIt is 100% likely that you will receive allocation if you own shares now, it is precisely a Rights Issue! It is guaranteed up to 190 million, not subscribed. - 2 päivää sitten2 päivää sittenRedEye: With cash at hand plus the proceeds from the gross SEK200m rights issue, we believe the company is funded through 2027. We estimate the company could become cash flow neutral by H2 2027. There is some uncertainty as to the Spanish situation, however, which could affect this positively or negatively.·2 päivää sittenTomorrow last chance to participate in FE at 1.55, so that will probably push the price up now...
- ·20.2. · MuokattuIn Pharma, it's crucial to get the revenue going for one's product. That's what one lives and dies by in this industry. Something Onco has managed brilliantly. Of course, the share price should fall on a new issue. However, the market totally overreacted and the 50% fall was almost comical. 5-10% and down to a price around 2.60 would have been more realistic. This is a buying opportunity. The market also seems to realize this and a price recovery has begun.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sittenPerhaps it's been said, but Onco is being heavily shorted because the expectation is that the price will go down in connection with the issue. This means that a number of millions of shares will be bought back from the short sellers and the price should then make an upward rebound next week.·18 t sittenDidn't go down last time, probably won't go down now... so that will be great!!
- ·1 päivä sittenOn its way up again!? The 40% drop came immediately after the emission announcement (dilution 33%), which means that most of the negative etc. is already priced in! The emission of approx. 200 Mkr secures financing for the Pepaxti launch in Europe and according to RedEye financing until 2027 with a base target price of 2.8. Pepaxti sales have shown strong growth historically. The gross margin is very high around 98%, which means that profitability can come quickly with volume scaling. Biotech often bottoms out around financing concerns, and once capital is secured, the focus usually shifts back to sales and pipeline.·1 päivä sittenI largely agree with you. There are two simple details here and that is the operating revenues that have increased significantly. If one gets revenues to increase, it often means market shares which in turn means acceptance in the market for the products. Then it's just the rest to sort out..... 😉
- ·1 päivä sittenRegardless of what one believes & hopes for the future, today is the last day to buy shares for those who want to participate in the new share issue at 1,55kr. As RedEye wrote, current cash + contribution from FE is expected to last until 2027... with a base price of 2,8 as a guideline until more positive news comes, and there's a lot brewing, so who knows when it will take off. 1,55 feels regardless like a really good buy in my opinion.·1 päivä sittenHippo: I believe in a bright future regarding ONCO. I also intend to participate in the new share issue. BUT how big is the chance that one actually gets to participate even if one owns shares today? It's already 90% subscribed by the major shareholders? Then there are certainly those who have submitted by mail to the company that they want allocation and are first in line. I think the chance is small. Or are you of a different opinion?·1 päivä sittenIt is 100% likely that you will receive allocation if you own shares now, it is precisely a Rights Issue! It is guaranteed up to 190 million, not subscribed.
- 2 päivää sitten2 päivää sittenRedEye: With cash at hand plus the proceeds from the gross SEK200m rights issue, we believe the company is funded through 2027. We estimate the company could become cash flow neutral by H2 2027. There is some uncertainty as to the Spanish situation, however, which could affect this positively or negatively.·2 päivää sittenTomorrow last chance to participate in FE at 1.55, so that will probably push the price up now...
- ·20.2. · MuokattuIn Pharma, it's crucial to get the revenue going for one's product. That's what one lives and dies by in this industry. Something Onco has managed brilliantly. Of course, the share price should fall on a new issue. However, the market totally overreacted and the 50% fall was almost comical. 5-10% and down to a price around 2.60 would have been more realistic. This is a buying opportunity. The market also seems to realize this and a price recovery has begun.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sittenPerhaps it's been said, but Onco is being heavily shorted because the expectation is that the price will go down in connection with the issue. This means that a number of millions of shares will be bought back from the short sellers and the price should then make an upward rebound next week.·18 t sittenDidn't go down last time, probably won't go down now... so that will be great!!
- ·1 päivä sittenOn its way up again!? The 40% drop came immediately after the emission announcement (dilution 33%), which means that most of the negative etc. is already priced in! The emission of approx. 200 Mkr secures financing for the Pepaxti launch in Europe and according to RedEye financing until 2027 with a base target price of 2.8. Pepaxti sales have shown strong growth historically. The gross margin is very high around 98%, which means that profitability can come quickly with volume scaling. Biotech often bottoms out around financing concerns, and once capital is secured, the focus usually shifts back to sales and pipeline.·1 päivä sittenI largely agree with you. There are two simple details here and that is the operating revenues that have increased significantly. If one gets revenues to increase, it often means market shares which in turn means acceptance in the market for the products. Then it's just the rest to sort out..... 😉
- ·1 päivä sittenRegardless of what one believes & hopes for the future, today is the last day to buy shares for those who want to participate in the new share issue at 1,55kr. As RedEye wrote, current cash + contribution from FE is expected to last until 2027... with a base price of 2,8 as a guideline until more positive news comes, and there's a lot brewing, so who knows when it will take off. 1,55 feels regardless like a really good buy in my opinion.·1 päivä sittenHippo: I believe in a bright future regarding ONCO. I also intend to participate in the new share issue. BUT how big is the chance that one actually gets to participate even if one owns shares today? It's already 90% subscribed by the major shareholders? Then there are certainly those who have submitted by mail to the company that they want allocation and are first in line. I think the chance is small. Or are you of a different opinion?·1 päivä sittenIt is 100% likely that you will receive allocation if you own shares now, it is precisely a Rights Issue! It is guaranteed up to 190 million, not subscribed.
- 2 päivää sitten2 päivää sittenRedEye: With cash at hand plus the proceeds from the gross SEK200m rights issue, we believe the company is funded through 2027. We estimate the company could become cash flow neutral by H2 2027. There is some uncertainty as to the Spanish situation, however, which could affect this positively or negatively.·2 päivää sittenTomorrow last chance to participate in FE at 1.55, so that will probably push the price up now...
- ·20.2. · MuokattuIn Pharma, it's crucial to get the revenue going for one's product. That's what one lives and dies by in this industry. Something Onco has managed brilliantly. Of course, the share price should fall on a new issue. However, the market totally overreacted and the 50% fall was almost comical. 5-10% and down to a price around 2.60 would have been more realistic. This is a buying opportunity. The market also seems to realize this and a price recovery has begun.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt